Form 4: Eli Lilly Director Acquires Shares Through Deferral Plan
SEC Form 4 Filing
Gabrielle Sulzberger, a director at Eli Lilly & Co, acquired 13 shares of common stock through a deferral plan on February 20, 2024.
Summary
- Gabrielle Sulzberger, a director at Eli Lilly & Co, acquired 13 shares of common stock on February 20, 2024.
- The shares were acquired at a price of $755.66 per share.
- The acquisition was made through the Lilly Directors' Deferral Plan, where the shares are deferred in lieu of cash compensation.
- The shares will be settled in common stock following Ms. Sulzberger's separation from service.
- Following the transaction, Ms. Sulzberger directly owns 2,098 shares of Eli Lilly common stock.
Sentiment
Score: 7
Explanation: The document reflects a routine transaction, a director acquiring shares through a deferral plan, which is generally viewed positively as it indicates confidence in the company. There are no negative implications.
Positives
- The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future.
Future Outlook
The acquired shares will be settled in common stock following the director's separation from service.
Industry Context
Director share acquisitions are a common occurrence in publicly traded companies and are often seen as a sign of confidence in the company's future performance.
Comparison to Industry Standards
- Director share acquisitions are a standard practice across the pharmaceutical industry, with companies like Pfizer, Johnson & Johnson, and Merck also having similar deferral plans for their directors.
- The number of shares acquired is relatively small, which is typical for director compensation through deferral plans.
- The price of $755.66 per share is consistent with the market price of Eli Lilly stock at the time of the transaction.
Stakeholder Impact
- The share acquisition by a director may have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 02/20/2024 | Date of the share acquisition by Gabrielle Sulzberger. |
| 02/21/2024 | Date the Form 4 was signed. |
Keywords
Eli Lilly, Director, Share Acquisition, Deferral Plan, Stock Ownership, LLY
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.